

Breelyn A Wilky

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/38524/publications.pdf>

Version: 2024-02-01

47
papers

1,428
citations

394421

19
h-index

361022

35
g-index

48
all docs

48
docs citations

48
times ranked

2605
citing authors

#	ARTICLE	IF	CITATIONS
1	Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 837-848.	10.7	262
2	Immune checkpoint inhibitors: The linchpins of modern immunotherapy. <i>Immunological Reviews</i> , 2019, 290, 6-23.	6.0	150
3	Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution. , 2019, 7, 213.		118
4	Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells. <i>PLoS ONE</i> , 2015, 10, e0133813.	2.5	88
5	Current and Future Directions for Angiosarcoma Therapy. <i>Current Treatment Options in Oncology</i> , 2018, 19, 14.	3.0	75
6	Extrathoracic Location and "Borderline" Histology are Associated with Recurrence of Solitary Fibrous Tumors After Surgical Resection. <i>Annals of Surgical Oncology</i> , 2013, 20, 4080-4089.	1.5	53
7	RNA helicase DDX3: a novel therapeutic target in Ewing sarcoma. <i>Oncogene</i> , 2016, 35, 2574-2583.	5.9	49
8	Desmoid fibromatosis: MRI features of response to systemic therapy. <i>Skeletal Radiology</i> , 2016, 45, 1365-1373.	2.0	46
9	Pericytoma With t(7;12) and ACTB-GLI1 Fusion. <i>American Journal of Surgical Pathology</i> , 2019, 43, 1682-1692.	3.7	45
10	LGR5 is Expressed by Ewing Sarcoma and Potentiates Wnt/ β 2-Catenin Signaling. <i>Frontiers in Oncology</i> , 2013, 3, 81.	2.8	41
11	Current status of immunotherapy for gastrointestinal stromal tumor. <i>Cancer Gene Therapy</i> , 2017, 24, 130-133.	4.6	40
12	A dose-finding study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcoma. <i>International Journal of Cancer</i> , 2013, 133, 997-1005.	5.1	39
13	Cell-Cycle Dependent Expression of a Translocation-Mediated Fusion Oncogene Mediates Checkpoint Adaptation in Rhabdomyosarcoma. <i>PLoS Genetics</i> , 2014, 10, e1004107.	3.5	38
14	A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours. <i>British Journal of Cancer</i> , 2015, 112, 24-31.	6.4	35
15	Local recurrence of soft-tissue sarcoma: issues in imaging surveillance strategy. <i>Skeletal Radiology</i> , 2018, 47, 1595-1606.	2.0	34
16	Value added. <i>Current Opinion in Oncology</i> , 2015, 27, 323-331.	2.4	27
17	Limb-sparing surgery plus radiotherapy results in superior survival: an analysis of patients with high-grade, extremity soft-tissue sarcoma from the <sc>NCDB</sc> and <sc>SEER</sc>. <i>Cancer Medicine</i> , 2018, 7, 4228-4239.	2.8	23
18	A Novel Chordoma Xenograft Allows In Vivo Drug Testing and Reveals the Importance of NF- κ B Signaling in Chordoma Biology. <i>PLoS ONE</i> , 2013, 8, e79950.	2.5	23

#	ARTICLE	IF	CITATIONS
19	A phase II study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcomas. <i>Clinical Sarcoma Research</i> , 2018, 8, 21.	2.3	22
20	Current Management of Angiosarcoma: Recent Advances and Lessons From the Past. <i>Current Treatment Options in Oncology</i> , 2021, 22, 61.	3.0	21
21	Pazopanib in sarcomas. <i>Current Opinion in Oncology</i> , 2013, 25, 373-378.	2.4	20
22	Future directions in soft tissue sarcoma treatment. <i>Current Problems in Cancer</i> , 2019, 43, 300-307.	2.0	17
23	Mutant IDH1 Depletion Downregulates Integrins and Impairs Chondrosarcoma Growth. <i>Cancers</i> , 2020, 12, 141.	3.7	17
24	Unmet Medical Needs and Future Perspectives for Leiomyosarcoma Patients—A Position Paper from the National Leiomyosarcoma Foundation (NLMSF) and Sarcoma Patients EuroNet (SPAEN). <i>Cancers</i> , 2021, 13, 886.	3.7	17
25	The Biology and Management of Cartilaginous Tumors: A Role For Targeting Isocitrate Dehydrogenase. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e648-e655.	3.8	13
26	Beyond Palliation: Therapeutic Applications Of ¹⁵³ Samarium-EDTMP. <i>Clinical & Experimental Pharmacology</i> , 2013, 03, .	0.3	12
27	Immunotherapy in sarcoma: a new frontier. <i>Discovery Medicine</i> , 2014, 17, 201-6.	0.5	12
28	The current landscape of early drug development for patients with sarcoma in the immunotherapy era. <i>Future Oncology</i> , 2018, 14, 1197-1211.	2.4	11
29	Considerations for immunotherapy in patients with cancer and comorbid immune dysfunction. <i>Annals of Translational Medicine</i> , 2021, 9, 1035-1035.	1.7	9
30	Immunotherapy in Sarcoma. <i>Surgical Oncology Clinics of North America</i> , 2022, 31, 381-397.	1.5	9
31	Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in <i>CTNNB1</i> or <i>APC</i> : A Multi-institutional Retrospective Study. <i>Clinical Cancer Research</i> , 2022, 28, 4092-4104.	7.0	8
32	Growing Pains: a Simulation-Based Curriculum for Improving the Transition to Hematology/Oncology Fellowship. <i>Journal of Cancer Education</i> , 2017, 32, 496-502.	1.3	7
33	Latest advances in adult gastrointestinal stromal tumors. <i>Future Oncology</i> , 2017, 13, 2183-2193.	2.4	7
34	MRI Volumetrics and Image Texture Analysis in Assessing Systemic Treatment Response in Extra-Abdominal Desmoid Fibromatosis. <i>Radiology Imaging Cancer</i> , 2021, 3, e210016.	1.6	7
35	Precision medicine in gastrointestinal stromal tumors. <i>Discovery Medicine</i> , 2019, 28, 267-276.	0.5	6
36	Malignant progression of a peripheral nerve sheath tumor in the setting of rhabdoid tumor predisposition syndrome. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27030.	1.5	3

#	ARTICLE	IF	CITATIONS
37	Myoepithelial carcinoma or epithelioid sarcoma – A rare diagnosis with poor prognosis. A case report and review of literature. International Journal of Surgery Case Reports, 2018, 49, 239-243.	0.6	3
38	A nonrandom association of sarcoidosis in patients with gastrointestinal stromal tumor and other sarcomas. Rare Tumors, 2018, 10, 203636131878762.	0.6	3
39	The Current Landscape of Early Drug Development for Patients With Sarcoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 807-810.	3.8	3
40	High grade sarcoma presenting as multifocal recurrent seromas after inguinal hernia repair: A case report. Rare Tumors, 2020, 12, 203636132097574.	0.6	2
41	Phase I open-label, ascending dose trial of AGEN1884, an anti-CTLA-4 monoclonal antibody, in advanced solid malignancies: Dose selection for combination with PD-1 blockade.. Journal of Clinical Oncology, 2018, 36, 3075-3075.	1.6	2
42	RNA helicase DDX3 is a novel therapeutic target for Ewing sarcoma.. Journal of Clinical Oncology, 2015, 33, 10026-10026.	1.6	1
43	A phase II study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcomas.. Journal of Clinical Oncology, 2015, 33, 10560-10560.	1.6	1
44	A pilot study of NY-ESO-1c259 T cells in subjects with advanced myxoid/round cell liposarcoma (NCT02992743).. Journal of Clinical Oncology, 2017, 35, TPS3097-TPS3097.	1.6	1
45	Emerging mechanisms of immunotherapy resistance in sarcomas. Cancer Drug Resistance (Alhambra,) Tj ETQq1 1 0,784314 rgBT /Ov	2.1	1
46	Panobinostat and carfilzomib cytotoxicity in IDH-mutant human chondrosarcoma.. Journal of Clinical Oncology, 2016, 34, 11027-11027.	1.6	0
47	Sounding the Alarm on Leiomyosarcoma Recurrence: Role of Circulating Tumor DNA. Clinical Cancer Research, 2022, , .	7.0	0